Antithrombotic Therapy for Mechanical Circulatory Support: Time to Throw the Baby (Warfarin) Out With the Bathwater (Aspirin)?

Overview

Journal Circ Heart Fail

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 25

PMID 39051102

Authors

Jane T Kelleher

Michael M Givertz

Affiliations

Soon will be listed here.

References

Nelson S, Giugliano R, Antman E, Park J, Norden A, Rost N . Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. J Clin Neurosci. 2021; 86:294-300. DOI: 10.1016/j.jocn.2020.10.036. View

Varshney A, Defilippis E, Cowger J, Netuka I, Pinney S, Givertz M . Trends and Outcomes of Left Ventricular Assist Device Therapy: JACC Focus Seminar. J Am Coll Cardiol. 2022; 79(11):1092-1107. DOI: 10.1016/j.jacc.2022.01.017. View

Connors J . On Target: Optimum International Normalized Ratio for Left Ventricular Assist Device Patients. Circ Heart Fail. 2016; 9(5). DOI: 10.1161/CIRCHEARTFAILURE.116.003166. View

Andreas M, Moayedifar R, Wieselthaler G, Wolzt M, Riebandt J, Haberl T . Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial. Circ Heart Fail. 2017; 10(5). PMC: 5434960. DOI: 10.1161/CIRCHEARTFAILURE.116.003709. View

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E . 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 149(1):e1-e156. PMC: 11095842. DOI: 10.1161/CIR.0000000000001193. View

Eikelboom J, Connolly S, Brueckmann M, Granger C, Kappetein A, Mack M . Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206-14. DOI: 10.1056/NEJMoa1300615. View

Mehra M, Netuka I, Uriel N, Katz J, Pagani F, Jorde U . Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial. JAMA. 2023; 330(22):2171-2181. PMC: 10640705. DOI: 10.1001/jama.2023.23204. View

Mavri A, Vene N, Bozic-Mijovski M, Miklic M, Soderblom L, Pohanka A . Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep. 2021; 11(1):13908. PMC: 8260635. DOI: 10.1038/s41598-021-93372-9. View

Netuka I, Tucanova Z, Ivak P, Gregor S, Kolesar D, Marek T . A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study. Circulation. 2024; 150(6):509-511. DOI: 10.1161/CIRCULATIONAHA.124.069726. View

10.

Mehra M, Goldstein D, Cleveland J, Cowger J, Hall S, Salerno C . Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. 2022; 328(12):1233-1242. PMC: 9459909. DOI: 10.1001/jama.2022.16197. View

11.

Terrovitis J, Ntalianis A, Kapelios C, Vakrou S, Diakos N, Katsaros L . Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device. Hellenic J Cardiol. 2015; 56(1):20-5. View

12.

Saeed D, Feldman D, El Banayosy A, Birks E, Blume E, Cowger J . The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update. J Heart Lung Transplant. 2023; 42(7):e1-e222. DOI: 10.1016/j.healun.2022.12.004. View

13.

Fralick M, Colacci M, Schneeweiss S, Huybrechts K, Lin K, Gagne J . Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. Ann Intern Med. 2020; 172(7):463-473. DOI: 10.7326/M19-2522. View

14.

Shah P, Looby M, Dimond M, Bagchi P, Shah B, Isseh I . Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study. JACC Heart Fail. 2024; 12(9):1540-1549. DOI: 10.1016/j.jchf.2024.04.013. View

15.

Glass C, Christakis A, Fishbein G, Watkins J, Strickland K, Mitchell R . Thrombus on the inflow cannula of the HeartWare HVAD: an update. Cardiovasc Pathol. 2018; 38:14-20. DOI: 10.1016/j.carpath.2018.09.002. View

16.

Numan L, Zimpfer D, Itzhaki Ben Zadok O, Aarts E, Morshuis M, Guenther S . Identifying patients at risk: multi-centre comparison of HeartMate 3 and HeartWare left ventricular assist devices. ESC Heart Fail. 2023; 10(3):1656-1665. PMC: 10192248. DOI: 10.1002/ehf2.14308. View

17.

Ellis D, Usman M, Milner P, Canafax D, Ezekowitz M . The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009; 120(12):1029-35, 2 p following 1035. DOI: 10.1161/CIRCULATIONAHA.109.856120. View

18.

Nguyen V, Stevens C, Brambatti M, Smith M, Braun O, Mariski Jr M . Improved Time in Therapeutic Range with International Normalized Ratio Remote Monitoring for Patients with Left Ventricular Assist Devices. ASAIO J. 2021; 68(3):363-368. DOI: 10.1097/MAT.0000000000001489. View

19.

Stevens S, Woller S, Kreuziger L, Bounameaux H, Doerschug K, Geersing G . Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021; 160(6):e545-e608. DOI: 10.1016/j.chest.2021.07.055. View

20.

Whitehouse K, Avula D, Kahlon T, Costelle D, Dunbar-Matos C, Pahwa S . Apixaban: Alternative Anticoagulation for HeartMate 3 Ventricular Assist Device. ASAIO J. 2022; 68(3):318-322. DOI: 10.1097/MAT.0000000000001650. View